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Summary
 
Two novel synthetic tetrapeptides, VEID-CHO and DMQD-CHO, could selectively inhibit
caspase-6 and caspase-3, respectively. We used these inhibitors to dissect the pathway of caspase
activation in Fas-stimulated Jurkat cells and identify the roles of each active caspase in apoptotic
processes. Affinity labeling techniques revealed a branched protease cascade in which caspase-8
activates caspase-3 and -7, and caspase-3, in turn, activates caspase-6. Both caspase-6 and -3
have major roles in nuclear apoptosis. Caspase-6 cleaves nuclear mitotic apparatus protein
(NuMA) and mediates the shrinkage and fragmentation of nuclei. Caspase-3 cleaves NuMA at
sites distinct from caspase-6, and mediates DNA fragmentation and chromatin condensation. It
is also involved in extranuclear apoptotic events: cleavage of PAK2, formation of apoptotic
bodies, and exposure of phosphatidylserine on the cell surface. In contrast, a caspase(s) distinct
from caspase-3 or -6 mediates the disruption of mitochondrial membrane potential (permeabil-
ity transition) and the shrinkage of cytoplasm. These findings demonstrate that caspases are or-
ganized in a protease cascade, and that each activated caspase plays a distinct role(s) in the exe-
cution of Fas-induced cell death. 
 
F
 
as/APO-1/CD95 is a cell-surface receptor essential for the
regulation of the immune system (1), especially for the
termination of T cell–mediated responses, the maintenance
of immune privilege (2), and the prevention of autoantibody
production (3). Evidence is accumulating that a family of
cysteine proteases, named caspases (4), play critical roles in
Fas-induced apoptotic cell death. The inhibition of caspases
by cowpox serpin CrmA or by synthetic peptide inhibitors
such as zVAD-fmk (benzyloxycarbonyl-Val-Ala-Asp(OMe)-
fluoromethylketone) and zDEVD-fmk (benzyloxycarbo-
nyl-Asp-Glu-Val-Asp(OMe)-fluoromethylketone), allows Fas-
stimulated cells to survive (5) and proliferate (6). Cross-linking
of the Fas receptor with Fas ligand (7) or with anti-Fas mAb
(8) recruits the death-inducing signaling complex (DISC)
 
1
 
consisting of FADD/MORT1 and pro–caspase-8 (MACH/
FLICE/Mch5) (9, 10). Pro–caspase-8 recruited to the DISC
is activated and released into the cytosol (11). The active
caspase-8 activates multiple caspases (12–14), which elicit
downstream biochemical changes such as mitochondrial
permeability transition (PT; 15), DNA fragmentation (16),
loss of nuclear lamina (17), and exposure of phosphati-
dylserine (PS) on the cell surface (18). Together, these
changes culminate in the process of apoptosis (19). How-
ever, the activation of caspases downstream of caspase-8 is a
poorly understood process. Nor is it clear which caspase(s)
contributes to each apoptotic biochemical or morphologi-
cal change. 
Each caspase family protease is present in nonapoptotic
cells as an inactive proenzyme. The enzyme becomes active
when the precursor is cleaved into a large subunit with a
molecular mass of 
 
z
 
20 kD and a small subunit with a mo-
lecular mass of 
 
z
 
10 kD, and forms a tetramer consisting of
two large and two small subunits (20). Most well-known
activation sites are immediately after aspartic acid (D) resi-
dues of pro-caspases (21), and the unique characteristic of
caspases is that they cleave after aspartic acids within their
 
1
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substrates (22). This suggests that caspases are activated by
autocatalysis or by mutual processing (23). Different cas-
cade pathways for the activation of caspases have been pro-
posed, based on the ability of certain recombinant caspases
to cleave and activate a limited spectrum of recombinant
pro-caspases in vitro and on the cleavage of endogenous
pro-caspases within cells in which a caspase(s) is exogenously
overexpressed (12, 24–26). However, these studies did not
identify the cascades that are induced in cells in response to
death-inductive stimuli. A study using YVAD-CHO, which
inhibits caspase-1 (IL-1
 
b
 
 converting enzyme; ICE), and
DEVD-CHO, which inhibits caspase-3 (CPP32/Yama/
apopain), indicated that there is a protease cascade in which
caspase-1–like activity is upstream of caspase-3–like activity
in Fas-mediated apoptosis of mouse W4 cells (27). How-
ever, the caspases involved in this cascade, especially the
identity of the caspase-1–like protease(s), remain unclear.
Affinity labeling techniques have been developed taking
advantage of the ability of active caspases, not their inactive
precursors, to bind their substrates. Derivatized peptides
mimicking substrates for caspases enter the substrate-binding
pockets of active caspases and irreversibly bind to the active
site cysteine in the large subunits, allowing their detection
on immunoblots (17, 28–30) or on histological sections (31).
Application of this technique, combined with inhibitor stud-
ies (14), identified multiple active caspases including caspase-
3–p20, caspase-3–p17, caspase-6 (Mch2), caspase-7 (Mch3/
ICE-LAP3/CMH-1), and caspase-8 in Fas-stimulated hu-
man Jurkat T cells. Stepwise appearances of active caspases
(14) were highly suggestive of a cascade of caspase activa-
tion. However, a sufficiently detailed dissection of the acti-
vation pathway would have required inhibitors with high
specificity for individual caspases, and the available caspase
inhibitors such as DEVD-CHO had too broad of a spec-
trum for this purpose. Although CrmA is rather selective
for caspase-1, -4, -5, and -8 (32–34), the inhibition of
caspase-8 by CrmA completely suppresses subsequent acti-
vation of other caspases (35). This has made further analysis
of downstream events difficult. 
Here, we demonstrated that novel tetrapeptide inhibitors,
VEID-CHO (acetyl-Val-Ileu-Asp-aldehyde) and DMQD-
CHO (acetyl-Asp-Met-Gln-Asp-aldehyde), can work as spe-
cific inhibitors of caspase-6 and -3, respectively. These re-
agents were used to analyze the caspase activation induced
by Fas ligation in Jurkat cells with that elicited by caspase-8
in cell-free Jurkat extracts. In each case, caspase-6 is acti-
vated downstream of caspase-3, forming a protease cascade.
Moreover, we identified the caspases upstream of each
caspase-dependent event in Fas-stimulated Jurkat cells.
 
Materials and Methods
 
Reagents.
 
Rabbit polyclonal antiserum against the large sub-
unit of caspase-7 (36) was provided by Gerald M. Cohen (Uni-
versity of Leicester, Leicester, UK). DMQD-CHO (14), VEID-
CHO (Peptide Institute, Osaka, Japan), and zVAD-fmk (Enzyme
Systems, Dublin, CA) were dissolved at 10 mM in DMSO and stored
at 
 
2
 
80
 
8
 
C. DiOC6(3) (3, 3
 
9
 
-dihexyloxacarbocyanine iodide; Mo-
lecular Probes Inc., Eugene, OR) was dissolved at 0.5 mM in DMSO
and stored at 
 
2
 
20
 
8
 
C. Propidium iodide (Calbiochem Corp., La
Jolla, CA) was dissolved in PBS at 100 
 
m
 
g/ml and stored at 4
 
8
 
C.
 
Inhibition of Caspases in Fas-stimulated Cells and in a Cell-free Re-
action Triggered by Caspase-8.
 
Jurkat cells were pretreated with
VEID-CHO or DMQD-CHO for 1 h at 37
 
8
 
C before stimulation
with anti-Fas mAb (CH-11, 100 ng/ml; reference 8). Preparation
of cytoplasmic extracts and the affinity labeling of active caspases
using YV(bio)KD-aomk (provided by Nancy A. Thornberry,
Merck, Rahway, NJ; reference 28) were performed as previously
described (14). Cytoplasmic extracts from logarithmically grow-
ing Jurkat cells were preincubated with VEID-CHO or DMQD-
CHO for 1 h at 37
 
8
 
C before the addition of purified recombinant
active caspase-8 to trigger the stepwise activation of caspases (14).
 
Single-cell Analysis of Intracellular Caspase Activity in Fas-stimu-
lated Jurkat Cells.
 
Jurkat cells (2.5 
 
3 
 
10
 
5
 
) treated with anti-Fas
mAb were gently centrifuged in a microfuge tube. The cell pellet
was resuspended with 50 
 
m
 
l of 10 
 
m
 
M PhiPhiLux-G2D2 sub-
strate solution (OncoImmunin, College Park, MD) in RPMI-1640
supplemented with 10% FCS. After incubation for 1 h at 37
 
8
 
C
avoiding direct light, the sample was diluted with 0.5 ml of ice-
cold flow cytometry dilution buffer (OncoImmunin) and filtered
through a nylon mesh to remove cell aggregates and/or debris.
Flow cytometric analysis was performed within 90 min of the end
of the incubation period using FACScan
 
Ò
 
 flow cytometer and
LYSIS II software (Becton Dickinson, Mountain View, CA).
 
Immunoblotting for the Cleavage of Caspase Substrates. 
 
Nuclei iso-
lated  from HeLa cells as described (37) were incubated with puri-
fied recombinant caspases, with 
 
Escherichia coli 
 
lysates containing
recombinant caspases (14), or with the extract from preapoptotic
chicken DU249 cells (S/M extract; reference 37). Whole cell ex-
tracts from Jurkat cells were obtained by adding SDS-PAGE sam-
ple buffer (50 mM Tris-HCl [pH 6.8], 15% sucrose, 3% SDS, and
0.01% bromophenol blue) to cell pellets and boiling for 3 min.
Proteins were resolved in SDS-PAGE gels, transferred to nitro-
cellulose membranes (Hybond ECL, Amersham Corp., Arlington
Heights, IL), and stained with rabbit polyclonal anti–nuclear mi-
totic apparatus protein (NuMA) antiserum (r240-C; reference
38), anti–poly (ADP-ribose) polymerase (PARP) mAb (C-2-10;
BIOMOL, Plymouth Meeting, PA), or rabbit polyclonal anti-
ste20-subdomain VI Ab (Upstate Biotechnology Inc., Lake
Placid, NY). Signals were visualized by enhanced chemilumines-
cence reagents (Amersham Corp.) according to the manufacturer’s
instructions.
 
Flow Cytometric Analysis of DNA Fragmentation, Mitochondrial
Membrane Potential, and Cell-surface Exposure of PS.
 
For the anal-
ysis of DNA fragmentation, Jurkat cells (10
 
6
 
) were permeabilized
by fixation with 70% ethanol for 2 h on ice, washed once with
PBS, treated with 10 
 
m
 
g/ml RNase A in PBS for 30 min at 37
 
8
 
C,
and incubated with 50 
 
m
 
g/ml propidium iodide for 30 min on
ice protected from light. For simultaneous recording of mito-
chondrial PT and PS externalization, Jurkat cells (5 
 
3 
 
10
 
5
 
) were
incubated with 40 nM DiOC6 (3) (Molecular Probes) together
with 1.5 
 
m
 
g/ml PE-conjugated annexin V (R&D Sys. Inc., Min-
neapolis, MN) in 10 mM Hepes/NaOH (pH 7.4), 140 mM
NaCl, 2.5 mM CaCl
 
2
 
 for 15 min at room temperature. Stained
cells were filtered through a nylon mesh and immediately sub-
jected to flow cytometry. 
 
Results
 
Affinity Labeling of Active Caspases in Fas-stimulated Jurkat
Cells. 
 
YV(bio)KD-aomk (28), an affinity-labeling reagent 
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for active caspases (14), recognized four major polypeptides in
Fas-stimulated Jurkat cells, designated F22, F20, F19, and
F17 according to their apparent molecular mass in kilodal-
tons (Fig. 1 
 
A
 
, lane 
 
1
 
). Previous studies revealed that these
correspond to caspase-7, caspase-3-p20, caspase-6, and
caspase-3-p17, respectively (14, 30). Using rabbit antise-
rum raised against caspase-7 (36), we have confirmed that
F22 corresponds to caspase-7 (Fig. 1 
 
B
 
, lane 
 
1
 
, and data not
shown).
 
Selective Inhibition of Caspase-6 by VEID-CHO. 
 
VEID-
CHO was synthesized based on the sequence within lamin
A cleaved by caspase-6, but not by caspase-3 or -7 (17, 39).
Caspase-3, -4, -6, -7, and -8 were expressed as recombi-
nant proteins in 
 
E. coli
 
 and tested for their sensitivities to
VEID-CHO. Caspase-4 (TX/ICH-2/ICErel-II) was in-
cluded because it is involved in the Fas-mediated apoptosis
of HeLa cells (40). As shown in Table 1, the activity of
caspase-6 was inhibited by VEID-CHO at concentrations
at least 100-fold lower than those required to inhibit
caspase-3, -4, -7, and -8. The active caspases in Fas-stimu-
lated Jurkat cells exhibited the sensitivities to VEID-CHO
similar to the recombinant proteins: F19/caspase-6 was at
least 100-fold more sensitive to VEID-CHO than were F22/
caspase-7, F20/caspase-3-p20, or F17/caspase-3-p17 (Ta-
ble 1). Therefore, VEID-CHO at 100 nM can work as a
selective inhibitor of caspase-6.
Studies in vitro have shown that caspase-6 can process pro-
caspase-3 (26, 41). A hypothetical cascade pathway has been
proposed in which caspase-3 and -7 are activated down-
stream of caspase-6 (24). Selective inhibition of caspase-6 ac-
tivity by VEID-CHO should block the activation of those
caspases activated downstream of caspase-6. Accordingly, Jur-
kat cells were exposed to VEID-CHO before stimulation
with anti-Fas mAb. As shown in Fig. 1 
 
A
 
, the activity of
F19/caspase-6 was inhibited by VEID-CHO partially at 1 
 
m
 
M
(lane 
 
4
 
) and completely at 10 
 
m
 
M (lane 
 
5
 
). Concentrations
of VEID-CHO in the culture medium required to inhibit
caspase-6 was much higher than in vitro experiments (Ta-
ble 1), most likely due to the impermeability of the plasma
membrane to the peptide inhibitor. Despite the loss of
F19/caspase-6 activity at 10 
 
m
 
M VEID-CHO, the labeling
of F22/caspase-7 and F20/caspase-3-p20 was unaffected
(Fig. 1 
 
A
 
, lane 
 
5
 
). Thus, caspase-3 and caspase-7 can be ac-
tivated independent of caspase-6 activity. Suppression of
F17/caspase-3-p17 labeling was observed at 10 
 
m
 
M (lane
 
5
 
), possibly because the activity of caspase-3-p17 may be
blocked at the effective intracellular concentration of VEID-
CHO, perhaps around 1 
 
m
 
M (Table 1). The loss of all
caspase labeling at 100 
 
m
 
M (lane 
 
6
 
) should reflect the ability
of VEID-CHO to inhibit caspase-8 at high concentrations
(Table 1), thereby preventing the processing of all down-
stream caspases. Indeed, the processing of pro–caspase-7
was blocked at 100 
 
m
 
M VEID-CHO, as discerned by reprob-
ing the same blot with anti–caspase-7 Ab (Fig. 1 
 
B
 
, lane 
 
6
 
).
Similar analysis was performed in cell-free conditions in
which the stepwise activation of caspases similar to that in
Fas-stimulated cells was induced by adding active recombi-
nant caspase-8 to cytoplasmic extracts from normally grow-
ing Jurkat cells (14). VEID-CHO at 10 nM added before
caspase-8 selectively blocked the activity of caspase-6 with
minimal effects on the activation of caspase-7, caspase-3-p20,
 
Table 1.
 
Effect of VEID-CHO on the Activity of Caspases
 
VEID-CHO F22 F20 F19 F17 Caspase-8 Caspase-7 Caspase-6 Caspase-3 Caspase-4
1 nM
 
1 1 1 1 1111 1
 
10 nM
 
11 6  
 
z
 
 2 1 1 
 
z
 
 616  
 
z
 
 21 1
 
100 nM
 
11 2 1  
 
z
 
 6 612 1  
 
z
 
 61
 
1 
 
m
 
M
 
61  
 
z
 
 6 2 6 
 
z
 
 26  
 
z
 
 26 26  
 
z
 
 21
 
10 
 
m
 
M
 
26  
 
z
 
 2 2 2 2222 1  
 
z
 
 6
 
100 
 
m
 
M
 
2 2 2 2 2222 2
 
Cytoplasmic extracts (30 
 
m
 
g total protein) from Jurkat cells treated with anti-Fas mAb for 3 h (F22, F20, F19, and F17), purified His-tagged caspase-8
(453 ng), or -6 (221 ng), and 
 
E. coli
 
 lysates containing caspase-7 (1.2 
 
m
 
g total protein), -3 (4.8 
 
m
 
g total protein), or -4 (2.1 
 
m
 
g total protein) were pre-
treated for 15 min at 37
 
8
 
C with VEID-CHO at concentrations indicated in 10-
 
m
 
l mixtures before labeling with 10 
 
m
 
M YV(bio)KD-aomk. 
 
1
 
, no
inhibition; 
 
6
 
 
 
z
 
 
 
2
 
, ,25% inhibition, 6, 25–75% inhibition; 6 z 2, 75–99% inhibition; 2, complete inhibition.
Figure 1. (A) Affinity label-
ing of caspases activated in Fas-
stimulated Jurkat cells and their
inhibition with VEID-CHO. Jur-
kat cells (106/ml), preincubated
for 1 h with indicated concentra-
tions of VEID-CHO at 378C in
5% CO2, were stimulated with
anti-Fas mAb (CH-11, 100 ng/
ml) in serum-free RPMI-1640
for 4 h at 378C. Cytoplasmic ex-
tracts from the cells were incu-
bated with 10 mM YV(bio)KD-aomk for 5 min at 378C, resolved in a
16% SDS-PAGE gel, and transferred to a nitrocellulose membrane. La-
beled caspases were visualized with horseradish peroxidase–conjugated
streptavidin and enhanced chemiluminescence. (B) Effect of VEID-CHO
on processing of pro–caspase-7. The same blot as in A was reprobed with
rabbit antiserum raised against the large subunit of caspase-7. The pro-
cessing of pro–caspase-7 (precursor) into the mature large subunit of
caspase-7 (p22), which comigrated with F22, is displayed. 590 Fas-induced Cascade Activation of Caspases and Downstream Processes
or caspase-3-p17 (data not shown). Taken together, these
results indicate that caspase-3 and -7 are activated indepen-
dently of caspase-6 in Fas-stimulated Jurkat cells.
Analysis of Caspase Cascade by Selective Inhibition of Caspase-3
with DMQD-CHO.  DMQD-CHO was synthesized based
on the cleavage site within protein kinase C d (PKCd). Al-
though PKCd is cleaved by caspase-3, it is not a substrate
for caspase-1, -2, -4, -5, -6, or -7 (42). Our previous study
showed that F20/caspase-3-p20 is inhibited at lower con-
centrations than either F22/caspase-7 or F19/caspase-6
(14). Caspase-8 is also relatively insensitive to DMQD-
CHO (data not shown). First, we investigated the effects of
DMQD-CHO on the cell-free activation of caspases in Jur-
kat cytoplasmic extracts triggered by recombinant caspase-8
(14). YV(bio)KD-aomk labeling of F20/caspase-3-p20 was
inhibited by DMQD-CHO at 1–2 mM (Fig. 2 A, lanes 4
and 5), the concentrations previously shown to block the
activity of F20/caspase-3-p20 (14). The labeling of F17/
caspase-3-p17 was also suppressed, most likely because the
cleavage of the prodomain of caspase-3-p20, which gener-
ates caspase-3-p17, is mediated by autocatalysis (25, 43). In-
terestingly, although the activity of F19/caspase-6 is insensi-
tive to DMQD-CHO even at 100 mM (14), the appearance
of F19/caspase-6 was prevented by the preincubation with
1–2 mM DMQD-CHO before the addition of caspase-8
(Fig. 2 A, lanes 4 and 5). This indicated that the activation
of F19/caspase-6 in response to caspase-8 is dependent on
the activity of F20/caspase-3-p20. This finding is supported by
a previous report in which efficient activation of caspase-6
by caspase-8 in a cell-free system requires the presence of
cytoplasmic extracts (13). This suggests that caspase-6 is ac-
tivated indirectly via another protease(s) present in the ex-
tracts. In contrast, the labeling of F22/caspase-7 was unhin-
dered up to 5 mM DMQD-CHO (lane 6). This indicated
that caspase-7 is activated independent of caspase-3 activity.
The loss of all labeling at 10 mM (lane 7) is due to the inhibi-
tion of caspase-8 (data not shown). 
We next tested whether caspase-3 can activate endoge-
nous pro-caspase-6 present in the extracts from normally
growing Jurkat cells. Although caspase-3 cleaves and acti-
vates recombinant pro-caspase-6 expressed in E. coli (26),
Orth et al. could not detect processing of pro-caspase-6 when
caspase-3 was added to extracts of nonapoptotic Jurkat cells
(24). We added recombinant active caspase-3 to the extract
and assessed the activity of caspase-6 by YV(bio)KD-aomk
affinity labeling. As shown in Fig. 2 B, the addition of
caspase-3 induced active F19/caspase-6 together with F20/
caspase-3-p20 (lanes 2–4). Thus, caspase-3 is able to activate
endogenous pro-caspase-6 in Jurkat cytoplasmic extracts,
supporting the existence of the protease cascade initiated
by caspase-8, in which caspase-6 is activated downstream of
caspase-3. Overexposure of the film showed that F22/
caspase-7 and F17/caspase-3-p17 are induced to a lesser
degree (data not shown). This suggests that caspase-3 can
also activate caspase-7 at much lower efficiency than
caspase-8. 
Are caspases organized in a similar cascade within Fas-
stimulated Jurkat cells? Preincubation of Jurkat cells with
10–100 mM DMQD-CHO before Fas receptor cross-link-
ing suppressed the labeling of F20/caspase-3-p20 and F17/
caspase-3-p17. Concomitant with the suppression of
caspase-3 activity, the appearance of F19/caspase-6 was also
blocked (Fig. 2 C, lanes 3 and 4). In contrast, the labeling
of F22 persisted up to 100 mM DMQD-CHO (Fig. 2 C,
lane 4). Reprobing of the same blot with anti–caspase-7 Ab
confirmed that F22 in the presence of 1–100 mM DMQD-
CHO corresponds to the large subunit of caspase-7 (data
not shown). As the concentration of DMQD-CHO re-
quired to block the activity of caspase-6 is z10-fold higher
than caspase-7 (14), the loss of caspase-6 labeling with pre-
served caspase-7 activity indicated that the suppression of
caspase-3-p20 activity resulted in the loss of caspase-6 acti-
vation. Time course studies (Fig. 2 D) demonstrated that
active F22/caspase-7 appeared at the same time point irre-
spective of the presence of DMQD-CHO. This result
showed that activation of caspase-7 was uninterrupted
when caspase-3 activity was blocked with 100 mM
DMQD-CHO.
Figure 2. (A) DMQD-CHO inhibits the caspase-8–triggered appear-
ances of active caspase-3 and caspase-6 in Jurkat cell extracts. Cytoplasmic
extracts (80 mg total protein) from normally growing Jurkat cells were
preincubated with the indicated concentrations of DMQD-CHO before
the addition of caspases-8 (680 ng). After incubation for 4 h at 378C, the
incubated mixtures were labeled with 10 mM YV(bio)KD-aomk (lanes
1–7). (B) Caspase-3 activates endogenous caspase-6 in Jurkat cytoplasmic
extracts. Purified recombinant caspase-3 (10 ng) was added to extracts
(70 mg total protein) from nonapoptotic Jurkat cells and incubated for the
indicated time periods (lanes 1–4, and 7) at 378C. Jurkat extracts alone
(lane 5) or caspase-3 alone (lane 6) were also incubated for 4 h at 378C.
The samples were treated with (lanes 1–6) or without (lane 7) 10 mM YV
(bio)KD-aomk. (C) Inhibition of caspase-6 activation in Fas-stimulated
Jurkat cells by the blockade of caspase-3 with DMQD-CHO. Jurkat cells
(106/ml) were pretreated with the indicated concentrations of DMQD-
CHO before Fas stimulation. Cytoplasmic extracts prepared from the cells
were incubated with (lanes 1–4) or without (lane 5) 10 mM YV(bio)KD-
aomk. (D) Time course of Fas-induced caspase activation in the presence
or absence of DMQD-CHO. Jurkat cells (106/ml), preincubated for 1 h
with (lanes 1–5) or without (6–10) 100 mM DMQD-CHO, were treated
with anti-Fas mAb for the time indicated, and their cytoplasmic extracts
were affinity labeled with 10 mM YV(bio)KD-aomk. (A–D) Labeled ac-
tive caspases were visualized with horseradish peroxidase–conjugated
streptavidin after electrophoresis in 16% SDS-PAGE gels and transfer to
nitrocellulose membranes. 591 Hirata et al.
Demonstration of Caspase Activity in Intact Fas-stimulated
Jurkat Cells Pretreated with DMQD-CHO.  We were con-
cerned about the possibility that caspase-7 was inhibited by
DMQD-CHO in Jurkat cells, whereas it was reactivated by
reversible dissociation from the inhibitor when the cells
were disrupted to prepare cytoplasmic extracts. Thus, we
measured caspase activity in intact Fas-stimulated cells by
flow cytometry, using PhiPhiLux-G2D2. This cell-perme-
able fluorescent substrate for caspases emits increased fluo-
rescence when it is proteolyzed within its PARP cleavage
site sequence (GDEVDGID). Since caspase-3 and -7 ap-
pear to be primarily responsible for PARP cleavage during
apoptosis (21), the increase in fluorescence should mainly
reflect the activities of caspase-3 and -7. Fig. 3 A depicts
time course studies displaying the forward light scatter (FSC),
an estimate of cell size, and the PhiPhiLux-G2D2 fluores-
cence of Jurkat cells (FL2). After Fas ligation, a gradual
augmentation of the PhiPhiLux-G2D2 fluorescence was
noted along with a decrease in FSC, suggesting the activa-
tion of caspases concomitant with the shrinkage of cyto-
plasm. The increase in fluorescence correlated well with
the kinetics of caspase activation measured by the ability of
Jurkat cytoplasmic extracts to cleave DEVD-MCA (14).
The enhanced PhiPhiLux-G2D2 fluorescence and the de-
crease in FSC was not observed on incubation of the cells
without anti-Fas mAb (data not shown). The increase in
fluorescence was abolished by the presence of 100 mM
zVAD-fmk (Fig. 3 A), a broad-spectrum caspase inhibitor
that blocks the activation of PARP-cleaving caspases (44),
supporting the notion that caspases are responsible for
cleavage of PhiPhiLux-G2D2. Lower fluorescence was ob-
served in the population of cells with the lowest FSC,
possibly due to the loss of the fluorescent molecules by
budding out of apoptotic bodies. In the presence of DMQD-
CHO at 100 mM, only minimal suppression of protease ac-
tivity was noted, with the PhiPhiLux-G2D2 fluorescence
significantly enhanced (Fig. 3 B, DMQD 100 mM) com-
pared with untreated cells (Fig. 3 B, control). This was con-
sistent with the persistence of caspase-7 activity demon-
strated by affinity labeling (Fig. 2 C, lane 4). As expected,
incubation with 100 mM DMQD-CHO alone without Fas
simulation did not induce the increase in PhiPhiLux-G2D2
fluorescence or cell shrinkage (data not shown). 
Dissection of Fas Signaling Pathways by Selective Caspase In-
hibitors.  Our results above indicated that VEID-CHO up
to 10 mM can selectively inhibit the activity of caspase-6,
and that 100 mM DMQD-CHO can selectively suppress
the activities of caspase-3 and -6 in Fas-stimulated Jurkat
cells (Fig. 4). We extended these findings to dissect the
events downstream of these caspases. In particular, events
downstream of caspase-6 should be blocked both by 10 mM
VEID-CHO and by 100 mM DMQD-CHO, whereas events
downstream of caspase-3 should be blocked only by 100 mM
DMQD-CHO. Processes unaffected by 10 mM VEID-
CHO or by 100 mM DMQD-CHO should be down-
stream of a caspase(s) distinct from caspase-3 and -6, or
caspase independent. Finally, all caspase-8–dependent events
should be suppressed by 100 mM VEID-CHO. 
Cleavages of Nuclear Substrates by Caspases.  NuMA, a struc-
tural protein localized in the nuclear matrix, is cleaved in
Fas-stimulated Jurkat cells (45, 46). Although NuMA
cleavage is blocked by broad-spectrum caspase inhibitors
such as DEVD-CHO and zVAD-fmk (45), it remained un-
settled whether the cleavage is directly catalyzed by a
caspase(s), or is due to a noncaspase protease(s) activated
downstream of a caspase(s) (47). We have found that re-
combinant and HeLa nuclear NuMA proteins are cleaved
at multiple sites by multiple distinct caspases active in a cell-
free system (data not shown) using extracts from preapop-
totic chicken DU249 cells (S/M extracts; reference 37). As
shown in Fig. 5 A, recombinant caspase-3 (lane 5), caspase-7
(lane 4), and caspase-4 (lane 3) cleaved NuMA in nuclei
isolated from HeLa cells, yielding fragments with an Mr of
z 190 and 180 kD. Time course studies revealed that the
190-kD fragment was the first to be detected, then disap-
peared as the 180-kD fragment gradually appeared (data
Figure 3. Flow cytometric analysis of caspase activity in Fas-stimulated
Jurkat cells. (A) Time course of Fas-induced caspase activation and cell
shrinkage. Jurkat cells (2.5 3 105) were treated with anti-Fas Ab (CH-11,
100 ng/ml) at 378C for the time indicated, followed by incubation with
10 mM PhiPhiLux-G2D2 substrate for 1 h. Three-dimensional display of
PhiPhiLux-G2D2 fluorescence (FL2) on a logarithmic scale, FSC on a
linear scale, and relative cell number on a linear scale are shown for each
time point. Arrowheads, baseline fluorescence of substrate-loaded cells in
the absence of caspase activation; zVAD-fmk, Jurkat cells were preincu-
bated with 100 mM zVAD-fmk for 1 h at 378C before the stimulation
with anti-Fas mAb for 4 h. (B) Effect of DMQD-CHO on caspase activ-
ity and cell size. Jurkat cells were preincubated in the absence or presence
of the indicated concentrations of DMQD-CHO before Fas stimulation
for 4 h. control, Jurkat cells before Fas stimulation. Dot plots showing fluo-
rescence intensity (FL2) on a logarithmic scale as a function of FSC on a
linear scale are presented. Dotted lines, average fluorescence of substrate-
loaded nonapoptotic cells. Histogram shows fluorescence intensity (FL2)
of the gated cells.
Figure 4. Protease cascade in
Fas-stimulated Jurkat cells and
the targets of tetrapeptide inhibi-
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not shown). This suggested that the 180 kD fragment was
derived from proteolysis of the 190-kD fragment. Caspase-6
also yielded a fragment with Mr of z160 kD in addition to
the 190- and 180-kD fragments (Fig. 5 A, lane 6). These
fragments comigrated with those detected in the cell-free
system composed of HeLa nuclei and S/M extracts (Fig. 5 A,
lane 7). Jurkat cells undergoing apoptosis in response to 1 mM
staurosporine (14) showed two distinct fragments of NuMA
with Mr of z180 and 160 kD (Fig. 5 A, lane 8) comigrat-
ing with those of HeLa nuclear NuMA generated by re-
combinant caspases or by caspases in S/M extracts. Similar
results were obtained using purified recombinant human
NuMA and recombinant caspase-3, -4, -6, -7, -8, or S/M
extracts (data not shown). Thus, these caspases can cleave
NuMA protein directly. 
Fas-stimulated Jurkat cells also showed two fragments of
NuMA with Mr of z180 and 160 kD (Fig. 5 B, lane 1). In
the presence of 1–10 mM VEID-CHO, the production of
the 160-kD fragment in Fas-stimulated Jurkat cells was
suppressed (Fig. 5 B, lanes 7 and 8), in parallel with the loss
of caspase-6 activity (Fig. 1 A, lanes 4 and 5). This is con-
sistent with the unique ability of recombinant caspase-6 to
generate the 160-kD fragment, and indicates that caspase-6
is responsible for the cleavage producing this fragment in
Fas-stimulated Jurkat cells. In contrast, the proteolysis yield-
ing the 180-kD fragments was not affected at 1 mM (Fig. 5 B,
lane 7). Although recombinant caspase-6 is able to produce
the 190- and 180-kD fragments in vitro, it is not the major
protease responsible for the production of those fragments
in apoptotic Jurkat cells. The moderate decrease in the
180-kD fragment at 10 mM VEID-CHO (Fig. 5 B, lane 8)
was considered to reflect the inhibition of the activities of
caspase-3-p17 as well as caspase-6 at this concentration
(Fig. 1 A, lane 5). Interestingly, 100 mM DMQD-CHO
blocked the generation of the 180-kD fragment as well as
the 160-kD fragment. These results indicated that caspase-3
is responsible for the production of the 180-kD fragment in
Fas-stimulated Jurkat cells. Although caspase-7 is able to
cleave HeLa nuclear and recombinant NuMA in vitro (Fig.
5 A, lane 4, and data not shown), the presence of caspase-7
activity alone was not sufficient for the cleavage of NuMA
in Fas-stimulated Jurkat cells. Thus, there is a discrepancy
between the cell-free and cellular results. 
This discrepancy may be explained by the unique intracel-
lular localization of caspase-7 within intact cells. Caspase-7
has been detected solely in the cytoplasm of Jurkat cells
Figure 5. (A) Cleavage of HeLa nuclear NuMA by recombinant
caspases. HeLa nuclei (1.3 3105) were incubated for 2 h at 378C with mi-
totic dilution buffer (37; lane 1), 884 ng purified His-tagged active
caspase-8 (lane 2), 70 mg E. coli lysate expressing caspase-4 (lane 3), 40 mg
E. coli lysate expressing caspase-7 (lane 4), 2.7 mg purified His-tagged ac-
tive caspase-3 (lane 5), 289 ng purified His-tagged active caspase-6 (lane
6), or 76 mg S/M extracts. Lane 8, whole cell extracts from Jurkat cells
(2 3 105) treated with 1 mM staurosporine for 3 h. (B–D) Effects of
DMQD-CHO and VEID-CHO on the cleavage of NuMA (B), PARP
(C), and PAK2 (D) in Fas-stimulated Jurkat cells. Whole cell extracts
from Fas-stimulated Jurkat cells preincubated with indicated concentra-
tions of DMQD-CHO or VEID-CHO were resolved in 5% (B) or 10%
(C and D) SDS-PAGE gels and transferred to nitrocellulose membranes.
Blots were probed with rabbit polyclonal anti-NuMA Ab (r240-C; A and
B), anti-PARP mAb (C-2-10; C), and rabbit polyclonal anti-ste20-sub-
domain VI Ab that stains PAK2 (D). 
Figure 6. Effects of DMQD-CHO and VEID-CHO on chromatin
condensation, nuclear shrinkage, and nuclear fragmentation. Jurkat cells
were preincubated for 1 h at 378C with 1% DMSO (b), with 1 mM (c), 10
mM (d), or 100 mM (e) VEID-CHO, or with 1 mM ( f ), 10 mM (g), or
100 mM (h) DMQD-CHO before stimulation with anti-Fas mAb for 4 h.
Jurkat cells were also incubated for 4 h without Fas stimulation (a). Cells
were fixed by 1% glutaraldehyde and stained with 2 mg/ml DAPI as pre-
viously described (14).593 Hirata et al.
(48), whereas caspase-3 can be detected in the nuclei of
some cell types (49) and of regressing, apoptotic neuroblas-
toma cells (50). In cell-free systems, nuclei may be perme-
abilized to some extent, allowing free entry of proteins
normally inaccessible to the intranuclear compartment. To
test this possibility, we examined whether the cleavage
of another nuclear substrate, PARP, is mediated solely by
caspase-3 in Jurkat cells. In contrast to NuMA, 100 mM
DMQD-CHO only weakly inhibited the PARP cleavage
(Fig. 5 C, lane 4). Suppression of caspase-6 activity with 1 mM
VEID-CHO did not affect the PARP cleavage (Fig. 5 C,
lane 6). Partial blockade of the cleavage with 10 mM VEID-
CHO (Fig. 5 C, lane 7) was likely to reflect the loss of
caspase-3-p17 activity (Fig. 1 A, lane 5). PARP cleavage
was markedly suppressed by 100 mM VEID-CHO (Fig. 5
C, lane 8). These indicated that caspase-3 is only partially
responsible for PARP cleavage within Fas-stimulated Jur-
kat cells. Thus, another caspase(s), most likely caspase-7,
cleaves PARP in the cells. This suggests that caspase-7 can
enter the nucleus and cleave its nuclear substrate(s). The
basis for the difference between caspase-3 and -7 in the
ability to cleave NuMA in Jurkat cells remained unclear.
 Role of Caspase-3 and -6 in Nuclear Apoptotic Changes.
The inhibition of caspase-3 plus -6 by 100 mM DMQD-
CHO completely blocked the nuclear morphological changes
as revealed by staining of chromatin structures with 49,6-
diamidino-2-phenylindole (DAPI; Fig. 6 h). In contrast,
the inhibition of caspase-6 alone with 10 mM VEID-CHO
resulted in the blockade of apoptotic morphology halfway
after the nuclear chromatin condensation into the nuclear
periphery (“rim collapse”; Fig. 6 d). These indicate that
caspase-3 is essential for the early morphological changes of
nuclei up to the rim collapse, whereas caspase-6 plays an
essential role in the late morphological changes such as the
shrinkage and fragmentation of apoptotic nuclei. This is
consistent with previous results in a cell-free system that a
lamin-cleaving caspase is responsible for the late nuclear
events, whereas a different caspase mediates the initiation of
nuclear morphological changes (51–53).
The principal role of caspase-3 and -6 in nuclear mor-
phological changes prompted us to examine whether these
proteases are upstream of DNA fragmentation, one of the
major biochemical changes in apoptotic nuclei (19). Flow
cytometric analysis of Fas-stimulated Jurkat cells stained with
propidium iodide displayed time-dependent increase in the
population of cells with subdiploid DNA contents and with
decreased FSC (Fig. 7 A), representing apoptotic cells with
DNA fragmentation and shrunken cytoplasm. Preincuba-
tion with VEID-CHO up to 10 mM did not prevent the
DNA fragmentation (Fig. 7 B), suggesting that the activity
of caspase-6 is not required. This is reminiscent of previous
results in a cell-free system where DNA fragmentation was
not affected by the inhibition of the lamin-cleaving caspase
(51, 52). When Jurkat cells were stimulated with anti-Fas
mAb in the presence of 100 mM DMQD-CHO, DNA frag-
mentation was completely inhibited (Fig. 7 B). Thus, frag-
mentation of DNA is an event downstream of caspase-3. It
Figure 7. Flow cytometric analysis of DNA fragmentation and cell
shrinkage. Dot plots depict DNA content quantitated by means of pro-
pidium iodide staining of ethanol-permeabilized cells on a logarithmic
scale (PI) as a function of FSC on a linear scale. (A) Time course of DNA
fragmentation and cell shrinkage in response to Fas ligation. (B) DMQD-
CHO at 100 mM inhibits DNA fragmentation without affecting cell shrink-
age, whereas100 mM VEID-CHO suppresses both. Jurkat cells were pre-
treated in the absence or presence of the indicated concentrations of
VEID-CHO or DMQD-CHO before Fas stimulation for 4 h. control, Jur-
kat cells before stimulation with anti-Fas mAb; dotted lines, the lower bor-
der of the distribution of FSC among normally growing Jurkat cells.
Figure 8. Effect of DMQD-CHO and VEID-CHO on cell shrinkage
and apoptotic body formation. Jurkat cells treated as described in Fig. 6
were visualized for cell morphology under phase contrast microscope.594 Fas-induced Cascade Activation of Caspases and Downstream Processes
is interesting to note that the addition of caspase-7 to a cell-
free Jurkat extract induced fragmentation of nuclear DNA
without activation of caspase-3 or -6 (24). In contrast, the
activity of caspase-7 alone, preserved at 100 mM DMQD-
CHO (Fig. 2 C, lane 4), was not sufficient for the induc-
tion of DNA fragmentation in Fas-stimulated cells (Fig. 7 B).
Involvement of Caspase-3 in the Cleavage of p21-activated Kinase
2 and Apoptotic Body Formation.  DMQD-CHO at 100 mM
suppressed the appearance of the cell population with the
lowest FSC (Figs. 3 B and 7 B), whereas VEID-CHO at 10
mM had no effect (Fig. 7 B). This raised the possibility that
caspase-3 has a role in cytoplasmic process(es), most likely
in the formation of apoptotic bodies. Phase contrast mi-
croscopy revealed that Fas-stimulated Jurkat cells formed
no apoptotic bodies in the presence of 100 mM DMQD-
CHO (Fig. 8 h), whereas VEID-CHO up to 10 mM did
not prevent apoptotic body formation (Fig. 8, c and d).
These indicated that caspase-3 is upstream of the apoptotic
body formation. 
We therefore tested whether caspase-3 is responsible for
the cleavage of p21-activated kinase (PAK)2, which mediates
the formation of apoptotic bodies in Fas-stimulated Jurkat
cells (54). Immunoblotting using Ab raised against the con-
served region within kinase domains of PAK family kinases
showed that the 65-kD PAK2 protein is cleaved in Fas-
stimulated Jurkat cells, yielding a 34-kD COOH-terminal
fragment (Fig. 5 D, lane 2) as previously described (54).
The cleavage of PAK2 was suppressed by 100 mM
DMQD-CHO (lane 4). VEID-CHO up to 10 mM failed to
affect the PAK2 cleavage (lanes 5–7), suggesting that
caspase-6 is not involved. Taken together, these results sug-
gested that caspase-3 is mainly responsible for the apoptotic
cleavage of PAK2 in Fas-stimulated Jurkat cells.
Identification of Caspases Upstream of Extranuclear Morpho-
logical and Biochemical Changes.  The shrinkage of cytoplasm
in Fas-stimulated Jurkat cells proceeded to a significant de-
gree despite the blockade of both caspase-3 and -6 by 100
mM DMQD-CHO (Figs. 3 B and 7 B). Although the se-
lective blockade of caspase-6 with 10 mM VEID-CHO had
no effect on cell size (Fig. 7 B), the broad-spectrum block-
ade of all caspases at 100 mM VEID-CHO markedly sup-
pressed the decrease in cell size (Fig. 7 B). The shapes of
cells observed by phase contrast microscopy were consistent
with the flow cytometric data. Neither 100 mM DMQD-
CHO (Fig. 8 h) nor 10 mM VEID-CHO (Fig. 8 d) affected
the Fas-induced shrinkage of Jurkat cells. In contrast, cyto-
plasmic shrinkage was completely blocked with 100 mM
VEID-CHO (Fig. 8 e). Taken together, a caspase(s) other
than caspase-3 or -6 plays a critical role(s) in the Fas-induced
shrinkage of cytoplasm. 
To delineate further the involvement of each caspase in
extranuclear processes, we examined apoptotic biochemical
changes in mitochondria and the plasma membrane. Break-
down of the inner mitochondrial membrane potential (mi-
tochondrial PT) is one of the earliest biochemical changes
in cells undergoing apoptosis (55, 56). Although recent re-
ports indicate that Fas-induced PT is dependent on the ac-
tivity of caspases (5, 15, 57), it remained to be determined
which caspase(s) is upstream of PT in the cells. The loss of
plasma membrane asymmetry, resulting in the surface ex-
posure of PS (58) and phosphatidylethanolamine (59), is
another characteristic apoptotic change. Fas-induced PS ex-
ternalization depends on the activity of caspases (18). We
measured PT and PS externalization by double staining
with DiOC6(3), the fluorescent probe that is sequestered to
mitochondria depending on the membrane potential (60),
and PE-conjugated annexin V, a natural protein that binds
PS exposed to the cell surface with high affinity (61). As
shown in Fig. 9 A, a cell population with decreased
DiOC6(3) uptake and increased annexin V binding was
first noted at 1 h after Fas ligation. This population with
collapsed mitochondrial membrane potential and with ex-
ternalized PS increased over time. Neither PT nor PS ex-
ternalization were affected by 10 mM VEID-CHO (Fig. 9 B).
The blockade of all caspases with 100 mM VEID-CHO
markedly inhibited both processes (Fig. 9 B), confirming pre-
vious reports that those events are downstream of caspases.
DMQD-CHO at 100 mM suppressed the increase in an-
nexin V binding (Fig. 9 B). Thus, the activity of caspase-3
is essential for PS externalization. In contrast, PT was not
affected by 100 mM DMQD-CHO, indicating that a
caspase(s) other than caspase-3 or -6 is involved in the dis-
ruption of mitochondrial membrane potential in Fas-stim-
ulated Jurkat cells. 
Discussion
The present study established the existence of a protease
cascade, in which caspase-3 mediates the activation of
caspase-6 triggered by Fas or by caspase-8 in the cytoplasm
of Jurkat cells. Selective inhibition of caspase-3 by 100 mM
DMQD-CHO blocked the activation of caspase-6. It is
Figure 9. (A) Time course of cell surface exposure of PS and mito-
chondrial PT. Jurkat cells (5 3 105) were treated with anti-Fas Ab for the
time indicated, and double stained with PE–annexin V and DiOC6(3).
(B) Effect of DMQD-CHO and VEID-CHO on PS externalization and
on mitochondrial PT. Jurkat cells were pretreated for 1 h with the indi-
cated concentrations of the inhibitors before Fas stimulation for 4 h. 595 Hirata et al.
formally possible that pro-caspase-6 is processed by another
noncaspase protease(s) sensitive to DMQD-CHO. How-
ever, the stepwise activation of caspases triggered by recom-
binant caspase-8 was observed in the Jurkat cytoplasmic ex-
tracts in the presence of protease inhibitors including PMSF,
aprotinin, chymostatin, leupeptin, antipain, pepstatin, and
EGTA (14). Even in this condition (unfavorable for most
serine-, cysteine-, and metalloproteinases), pro-caspase-6
was processed to the active form unless the activation was
blocked by 100 mM DMQD-CHO. Thus, it is likely that
caspase-3 directly processes and activates caspase-6 in the
cytoplasm of Jurkat cells.
The ability of caspase-8 to induce stepwise activation of
caspases in organelle-free cytoplasmic extracts of Jurkat cells
(14) suggests that mitochondria are dispensable for the or-
ganization of this protease cascade in Jurkat cells. However,
this does not rule out the possibility that caspase-8 indi-
rectly activates caspase-3 by inducing mitochondrial release
of cytochrome c (62, 63) and/or AIF (57) in other cell
types. In cells with more cytoplasm and a lower concentra-
tion of pro-caspase-3, caspase-8 activated in the DISC on
the plasma membrane and released into the cytoplasm
might not process cytoplasmic pro-caspase-3 efficiently. The
sequestration of caspase-8 to the mitochondria (64) and the
subsequent release of cytochrome c and AIF could well fa-
cilitate the activation of caspase-3. This pathway should be
particularly active in cells rich in mitochondria. The exist-
ence of both direct and indirect pathways for the activation
of caspase-3 by caspase-8 would explain the differences
among cell types in the protective effect of Bcl-2 and Bcl-xL
on Fas-induced cell death (15, 35). In cells that predomi-
nantly use the indirect pathway for caspase-3 activation,
Bcl-2 family proteins may inhibit Fas-induced apoptosis by
blocking the release of cytochrome c and/or AIF from mi-
tochondria. 
It seems unlikely that caspase-8 activates caspase-3 via other
caspases. Affinity labeling displayed three other caspases,
caspase-7, caspase-6, and F25, in Fas-stimulated Jurkat cells (14).
Inhibitor studies with VEID-CHO showed that caspase-6
activity is not required for the activation of caspase-3. How-
ever, recent evidence suggests that different caspase cascades
may be used depending on cell types and death-inductive
stimuli (65). In some cell death events, caspase-6 may act
upstream of caspase-3 (24, 41). The appearance of F25 is a
delayed event, much later than caspase-3, -7, and -6 (14).
Therefore, it seems unlikely that F25 is upstream of other
caspases. Previous studies indicated that recombinant caspase-7
cannot process recombinant pro-caspase-3 (66). Indeed,
the addition of recombinant active caspase-7 to the extracts
from normally growing Jurkat cells failed to induce F20/
caspase-3-p20 (data not shown). Overall, our findings
strongly suggested that there is a direct two-step protease
cascade in Fas-stimulated Jurkat cells, in which caspase-8 ac-
tivated via FADD/MORT1 cleaves pro-caspase-3, and the
activated caspase-3 in turn activates caspase-6 by directly
cleaving pro-caspases-6 (Fig. 10). 
In contrast to caspase-6, caspase-7 is activated indepen-
dent of caspase-3, since caspase-7 remained active despite
the complete blockade of caspase-3 and -6 by 100 mM
DMQD-CHO. It is unlikely that caspase-7 is activated in-
dependent of caspase-8. Caspase-8 is the only active caspase
highly sensitive to cowpox CrmA in Fas-stimulated Jurkat
cells (14) and the inhibition of caspase-8 by CrmA com-
pletely prevents the processing of pro–caspase-7 (35). The
addition of caspase-8 to the extracts from proliferating Jur-
kat cells led to the appearance of both active caspase-7 and
caspase-3-p20 (14). These findings further support the idea
that pro-caspase-7 is directly cleaved and activated by
caspase-8 (12, 13) in Fas-stimulated Jurkat cells (Fig. 10). It
should be noted, however, that the affinity labeling method
may not be able to detect a certain active caspase(s) (14).
The possibility has not been excluded that such an unde-
tectable caspase(s) plays a functional role(s) in Fas-induced
apoptosis. Therefore, the Fas signaling pathway depicted in
Fig. 10 is better viewed as a framework for future studies.
Detailed analyses of Fas-induced signaling using VEID-
CHO and DMQD-CHO provided evidence that the pro-
tease cascade bifurcates into a caspase-7 arm and a caspase-3
arm, each inducing distinct downstream intracellular events
(Fig. 10). There is a point of ramification in the Fas signal-
ing pathway at the level of the caspase cascade.
Caspase-3 Arm. The caspase-3 arm seems to play major
roles in the execution of nuclear apoptosis. Caspase-3 acti-
vates caspase-6, which in turn plays an essential role in the
induction of nuclear shrinkage and nuclear fragmentation.
Cleavage of the nuclear structural protein NuMA is medi-
ated exclusively by the caspases of this branch. DNA frag-
mentation, a hallmark of nuclear apoptosis (67), is down-
stream of caspase-3. This is consistent with the result in a
cell-free system showing that caspase-3 is a direct activator
of DNA fragmentation factor (DFF; reference 16). DFF can
induce DNA ladder in isolated nuclei only after its 45-kD
subunit is cleaved by caspase-3. Our present data support
the idea that caspase-3 mediates DNA fragmentation by
cleaving DFF in Fas-stimulated Jurkat cells. 
Microscopic analysis of DAPI-stained nuclei indicated
that caspase-3 has a role in the initiation of chromatin con-
densation. PKCd is cleaved and activated by caspase-3, not
by caspase-6 or -7 (42). By undetermined mechanisms, in-
troduction of cleaved active PKCd fragment to HeLa cells
induces nuclear apoptotic changes, including chromatin con-
Figure 10. Schematic representation of Fas-induced caspase activation
and signaling pathways downstream of caspases. Solid arrows, direct inter-
actions; dashed arrows, indirect or incompletely defined interactions. 596 Fas-induced Cascade Activation of Caspases and Downstream Processes
densation (42). This may underlie the ability of caspase-3 to
initiate the nuclear apoptotic morphological changes. 
Although caspase-3 plays major roles in nuclear apop-
totic events, it is also involved in extranuclear processes. PS
exposed on the cell surface is recognized by macrophages
and triggers the engulfment of apoptotic cells by phago-
cytes (58). Our results indicated that this PS externalization
in response to Fas ligation is downstream of caspase-3. The
molecular mechanism by which caspase-3 mediates PS ex-
ternalization remains to be determined. It has been sug-
gested that PS exposure results from the inactivation of
aminophospholipid translocase and the enhanced activity of
scramblase (68). In the recently reported amino acid se-
quence of scramblase (69), however, no canonical consen-
sus sequence for caspase-3 cleavage (22) was identified. We
found that caspase-3 is a principal mediator of the apoptotic
body formation. This may reflect the fact that PAK2 cleav-
age in Fas-stimulated Jurkat cells is mainly catalyzed by
caspase-3. Alternatively, the apoptotic body formation may
be coupled to nuclear events, as suggested by the exclusion
of Ro, La, and small nuclear ribonucleoproteins (snRNPs)
from the nucleoplasms and the clustering of these ribonucleo-
proteins in apoptotic bodies (70).
Caspase-7 Arm. The caspase-7 arm is involved in the
Fas-induced signaling in a manner distinct from caspase-3
and -6. Our results suggested that caspase-7 catalyzes, to-
gether with caspase-3, the cleavage of a nuclear substrate,
PARP. This result accords well with the analysis of caspase-3
knockout mice showing that the PARP cleavage in apop-
totic thymocytes is seemingly unaffected by the loss of
caspase-3 (65). Thus, caspase-7 can compensate for some of
the apoptotic biochemical events mediated by caspase-3. 
Our observations suggest that caspase-7 also has a role(s)
in the Fas-induced signaling that are not redundant with
caspase-3. Apoptotic shrinkage of cytoplasm (19) persisted
in the presence of 100 mM DMQD-CHO, which blocked
caspase-3 and -6. A recent report described a similar partial
blockade of apoptotic events in KB epidermal carcinoma
cells. zDEVD-FK at 50 mM abolished Fas-induced chro-
matin condensation and apoptotic body formation, whereas
surface blebbing, cell shrinkage, the disruption of actin net-
work, and the activation of stress-activated MAP kinases,
c-Jun NH2-terminal kinase (JNK)/stress-activated protein
kinase (SAPK) and p38, remained uninterrupted (71). In
contrast, the blockade of all caspases with 100 mM VEID-
CHO abolished the cell shrinkage. Caspase-7, active in the
presence of DMQD-CHO, may thus mediate cell shrink-
age. Although caspase-8 might mediate cell shrinkage, ac-
tive caspase-8 was not detected in staurosporine-induced
apoptosis of Jurkat cells (14) in which cytoplasmic shrink-
age is prominent. Further, although caspase-3 and -7 have
closely related structures (66) and almost identical prefer-
ences for tetrapeptide substrates (72, 73), caspase-7 may
play a role(s) distinct from caspase-3. In this regard, it is of
interest that caspase-3 and -7 have different optimal pH
ranges (74). Further elucidation of cytoplasmic substrates
specific for caspase-7 may clarify its role(s) in the cytoplas-
mic shrinkage induced by Fas ligation.
Can Caspase-7 Substitute for Caspase-3? A controversial
issue is whether caspase-7 can substitute for caspase-3. The
substrate specificity of caspase-7 is similar to caspase-3 (72,
73), although caspase-7 cannot cleave some caspase-3 sub-
strates such as PKCd (42) and pro-caspase-6 (26). This study
demonstrated that many biochemical changes of Fas-induced
apoptosis in Jurkat cells are mediated solely by caspase-3
(Fig. 10). However, in knockout mice deficient in caspase-3,
most apoptotic events are not interrupted, except for those
in neuronal development (65). One attractive possibility is
that caspase-3 and -7 compete for a common cofactor(s) to
fulfill their intracellular functions. In Jurkat cells, caspase-3 in-
activated by 100 mM DMQD-CHO may still compete
with caspase-7 for the cofactor(s). In the absence of
caspase-3 protein (65), however, caspase-7 may be free to
use the cofactor(s) and thus to compensate for the loss of
caspase-3 protein. 
Mitochondrial PT. Analysis of the mitochondrial trans-
membrane potential in Fas-stimulated cells showed that a
caspase(s) other than caspase-3 or -6 is required for PT.
Since the cell shrinkage is also mediated by a caspase(s) other
than caspase-3 or -6, PT may be upstream of Fas-induced
cytoplasmic shrinkage. It is of interest in this regard that the
caspase-independent cell death induced by Bax, which may
be a direct trigger of PT (75), is accompanied by PT and
cell shrinkage (5). Because AIF is released on PT and acti-
vates DNase involved in internucleosomal DNA cleavage
(76), it is surprising that DNA fragmentation was not observed
despite the occurrence of PT in the presence of 100 mM
DMQD-CHO. It is unclear whether the release of AIF is
inhibited in the presence of DMQD-CHO, whether the
activity of AIF is suppressed by the inhibitor, or whether the
activity of AIF alone is not sufficient for the induction of
DNA fragmentation.
We could not unequivocally determine which caspase is
upstream of PT in Fas-stimulated Jurkat cells. However, it
has been reported that caspase-8 transfected to 293T cells can
form a complex with cotransfected Bcl-xL (64). If caspase-8
is recruited to mitochondria via complex formation with
such Bcl-2 family proteins, it might act on mitochondrial
substrates and disrupt the membrane potential. The devel-
opment of an inhibitor(s) selective for caspase-7 should al-
low the identification of a caspase(s) responsible for such
extranuclear events as PT and cytoplasmic shrinkage.
Cell-free versus Cellular Apoptosis. A constant concern of
in vitro studies is their applicability to intact cells. Although
caspase-7 cleaves recombinant and HeLa nuclear NuMA in
vitro, the endogenous NuMA of Jurkat cells remained un-
cleaved despite caspase-7 activation. Despite the ability of
caspase-6 to generate the 180-kD fragment in vitro, only
caspase-3 was responsible for this cleavage in Fas-stimulated
Jurkat cells. Similarly, caspase-7 combined with extracts from
nonapoptotic cells can induce DNA fragmentation in iso-
lated nuclei, without activation of caspase-3 (24). How-
ever, a blockade of caspase-3 abolished DNA fragmenta-
tion within Fas-stimulated Jurkat cells despite persistent
caspase-7 activity. In contrast, it is worth noting that the
role of a lamin-cleaving protease(s), such as caspase-6, in597 Hirata et al.
the shrinkage and fragmentation of nuclei (Fig. 10) was first
established in a cell-free system (51, 52). Cell-free systems
have their own roles in the development of new tools and
concepts, which should be explored at the level of cells and
organisms (77).
Our approach exemplified the use of synthetic inhibitors
that are relatively selective for each caspase. Recognition of
substrates that are cleaved by one or a few caspases (17, 42)
is a vital step in the design of such selective caspase inhibi-
tors. The application of these reagents leads to effective ap-
proaches for dissecting the signaling pathways of apoptotic
cell death. Inhibitors are being designed as the results of
systematic screening of defined sequence variants of pre-
ferred substrates (72) and by use of the positional scanning
synthetic combinatorial library (73). Detailed analysis of
each cell death event using an array of inhibitors may iden-
tify targets for therapeutic interventions of the pathological
processes resulting from excessive (78) or inappropriately
suppressed (79) apoptosis.
Overall, the present study shows that the Fas-induced
apoptotic cell death process is an integration of multiple,
parallel biochemical events that occur downstream of the
activation of particular caspases. The apparent heterogene-
ity in the biochemistry of apoptosis in different systems
may be the result of the activation of different combina-
tions of caspases, and consequently from their organization
into various different protease cascades. 
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